In general terms, the anti-tumoural capacity of B cells has been described in some types of human cancers such as: CRC (due to the infiltration of CD20+ B cells, CD8+ T cells and B cell–attracting CXCL13) [415], melanoma (TLS densities) [378], ovarian cancer (CD20+ B cells and CD8+ T cells immune infiltrates) [416], breast cancer (CD20+ infiltration) [417], hepatocellular carcinoma (density of tumour-infiltrating CD19+ B cells) [418], HNSCC (peri-tumoural B cell infiltration) [419], or CRC (high infiltration of CD20+ B cells increased the prognostic effect of CD8+ T cells) [420]. Here, CD8A is linked to hepatocellular carcinoma.